GeneSystem Co

GeneSystem Co Share Buybacks

The Share Buybacks of GeneSystem Co (363250.KQ) as of Oct 22, 2026 is -1.31 B KRW. In the previous year, Share Buybacks was 242.47 M KRW — a change of -638.62% (lower).

Share Buybacks

-1.31 BKRW

YoY

-638.62%

Last updated:

Share Buybacks of GeneSystem Co is 2024 -1.31 B KRW. Share Buybacks of GeneSystem Co was 2023 242.47 M KRW. It decreases by -638.62% lower compared to the previous year.

The GeneSystem Co Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2018
3.00 B KRW
Jan 1, 2020
7.60 B KRW
Jan 1, 2021
29.65 B KRW
Jan 1, 2022
224.33 M KRW
Jan 1, 2023
242.47 M KRW
Jan 1, 2024
-1.31 B KRW
The GeneSystem Co Share Buybacks history
YEARShare BuybacksYoY
-1.31 BKRW-638.62%
242.47 MKRW+8.09%
224.33 MKRW-99.24%
29.65 BKRW+290.09%
7.60 BKRW+153.41%
3.00 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Share Buybacks of GeneSystem Co is -1.31 B KRW in 2024.

Share Buybacks of GeneSystem Co changed from 242.47 M KRW to -1.31 B KRW, representing a -638.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GeneSystem Co

All Key Metrics — GeneSystem Co